You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm's transplant allograft status test identifies genetic biomarkers that predict the likelihood of a patient's immune system to reject the organ over time.
The firm hopes its newly launched DxWound will improve pathogen detection in skin and soft tissue infections by including anaerobic and fungal microbes in its reports.
The study is the first to demonstrate the design features and operational characteristics of Cepheid's Xpert MTB/RIF Ultra assay.
Researchers used mass spectrometry to identify unique biochemical markers that differentiate Lyme disease from southern tick-associated rash Illness.
The ThromboSeq test detected early-stage cancer with 81 percent accuracy and late-stage cancer with 88 percent accuracy.
King's College London researchers reported that cardiac myosin-binding protein C might be more sensitive in detecting cell death due to a heart attack.
The firm is developing an electrochemical sensor platform to detect sepsis and other conditions using a single drop of blood and a single-use cartridge.
The test can measure lower levels of troponin, enabling doctors to more accurately identify patients who actually have an acute myocardial infarction.
The tests will enable clinicians to diagnose early-stage Alzheimer's disease more accurately by detecting biomarkers in cerebrospinal fluid.
The firm anticipates commercializing its protein biomarker-based test, which can provide a diagnosis in 90 seconds, in late 2017.